div class=ts-pagebutton class=gotoPage data-page=1Page 1button div class=ts-imagea href=https:reader042vdocumentsmxreader042viewer20220307075af523e37f8b9a154c8f47fehtml5page1jpg target=_blank img data-url=agreement-dated-may-26-2016-with-intas-pharmaceuticals-limited-for-sale-of-itshtmlpage=1 data-page=1 class=ts-thumb lazyload alt=Page 1: Agreement dated May 26 2016 with Intas Pharmaceuticals Limited for sale of its Biotech Business Unit as a going concern on a slump sale basis The same has been considered as a discontinuing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader042vdocumentsmxreader042viewer20220307075af523e37f8b9a154c8f47fehtml5thumbnails1jpg width=140 height=200 adivdivdiv class=ts-pagebutton class=gotoPage data-page=2Page 2button div class=ts-imagea href=https:reader042vdocumentsmxreader042viewer20220307075af523e37f8b9a154c8f47fehtml5page2jpg target=_blank img data-url=agreement-dated-may-26-2016-with-intas-pharmaceuticals-limited-for-sale-of-itshtmlpage=2 data-page=2 class=ts-thumb lazyload alt=Page 2: Agreement dated May 26 2016 with Intas Pharmaceuticals Limited for sale of its Biotech Business Unit as a going concern on a slump sale basis The same has been considered as a discontinuing loading=lazy src=data:imagegifbase64iVBORw0KGgoAAAANSUhEUgAAAAIAAAACCAQAAADYv8WvAAAAD0lEQVR42mP8X8AwAgiABKBAv+vAXklAAAAAElFTkSuQmCC data-src=https:reader042vdocumentsmxreader042viewer20220307075af523e37f8b9a154c8f47fehtml5thumbnails2jpg width=140 height=200 adivdiv
